Maarten Egeler

1.1k total citations
29 papers, 769 citations indexed

About

Maarten Egeler is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Maarten Egeler has authored 29 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Maarten Egeler's work include Hematopoietic Stem Cell Transplantation (11 papers), Histiocytic Disorders and Treatments (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Maarten Egeler is often cited by papers focused on Hematopoietic Stem Cell Transplantation (11 papers), Histiocytic Disorders and Treatments (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Maarten Egeler collaborates with scholars based in Netherlands, Canada and United States. Maarten Egeler's co-authors include Huib N. Caron, Rosalyn Slater, P.A. Voûte, Jos P.M. Bökkerink, Jan de Kraker, Peter van Sluis, A. Westerveld, Rogier Versteeg, Geneviève Laureys and Ann C. Mertens and has published in prestigious journals such as New England Journal of Medicine, Blood and Annals of Oncology.

In The Last Decade

Maarten Egeler

28 papers receiving 755 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maarten Egeler Netherlands 11 291 258 199 145 113 29 769
Maurizio Miano Italy 19 93 0.3× 620 2.4× 158 0.8× 137 0.9× 110 1.0× 68 1.1k
Dragana Janić Serbia 15 57 0.2× 181 0.7× 175 0.9× 88 0.6× 130 1.2× 70 722
Der-Cherng Liang Taiwan 10 89 0.3× 575 2.2× 344 1.7× 270 1.9× 91 0.8× 16 1.2k
Susan R. Wiersma United States 13 103 0.4× 260 1.0× 137 0.7× 78 0.5× 58 0.5× 16 517
Kate Wheeler United Kingdom 14 208 0.7× 189 0.7× 96 0.5× 104 0.7× 9 0.1× 30 668
Teena Bhatla United States 16 62 0.2× 215 0.8× 281 1.4× 261 1.8× 29 0.3× 35 788
J Akatsuka Japan 14 124 0.4× 403 1.6× 109 0.5× 112 0.8× 51 0.5× 43 734
Mary Taj United Kingdom 13 76 0.3× 91 0.4× 77 0.4× 219 1.5× 30 0.3× 29 550
Ronald L. Chard United States 17 151 0.5× 445 1.7× 147 0.7× 185 1.3× 18 0.2× 26 904
Meerim Park South Korea 16 36 0.1× 191 0.7× 90 0.5× 119 0.8× 44 0.4× 49 521

Countries citing papers authored by Maarten Egeler

Since Specialization
Citations

This map shows the geographic impact of Maarten Egeler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten Egeler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten Egeler more than expected).

Fields of papers citing papers by Maarten Egeler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maarten Egeler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten Egeler. The network helps show where Maarten Egeler may publish in the future.

Co-authorship network of co-authors of Maarten Egeler

This figure shows the co-authorship network connecting the top 25 collaborators of Maarten Egeler. A scholar is included among the top collaborators of Maarten Egeler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maarten Egeler. Maarten Egeler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ham, Renske M.T. ten, Maartje W. Rohaan, Maarten Egeler, et al.. (2025). Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial. Annals of Oncology. 36(10). 1154–1165. 1 indexed citations
3.
Patrick, Katharine, Muhammad Ali, Susan E. Richardson, et al.. (2015). The yield of monitoring for HSV and VZV viremia in pediatric hematopoietic stem cell transplant patients. Pediatric Transplantation. 19(6). 640–644. 5 indexed citations
4.
Lankester, Arjan C., Franco Locatelli, Peter Bader, et al.. (2014). Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. Biology of Blood and Marrow Transplantation. 21(3). 402–411. 9 indexed citations
5.
Gassas, Adam, Lillian Sung, Annie Dupuis, et al.. (2013). Acute gut GVHD in children: does skin involvement matter?. Bone Marrow Transplantation. 48(8). 1129–1132. 6 indexed citations
6.
Pole, Jason D., Adam Gassas, Maarten Egeler, et al.. (2013). SUBSEQUENT MALIGNANT NEOPLASMS (SMN) IN CHILDHOOD CANCER PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT). Pediatric Blood & Cancer. 60. 166–166. 1 indexed citations
7.
Engelen, Vivian, Hendrik M. Koopman, Symone Detmar, et al.. (2012). The influence of patient reported outcomes on the discussion of psychosocial issues in children with cancer. Pediatric Blood & Cancer. 59(1). 161–166. 33 indexed citations
8.
Gassas, Adam, Sharon Dell, John Doyle, et al.. (2012). Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT. Bone Marrow Transplantation. 48(6). 814–818. 8 indexed citations
9.
Ball, L.M., Maria Ester Bernardo, Maarten J. D. van Tol, et al.. (2011). Mesenchymal stromal cells are highly effective in steroid-refractory, grade III-IV acute graft-versus-host disease in children. Bone Marrow Transplantation. 46. 1 indexed citations
10.
Bartelink, Imke H., Robbert G. M. Bredius, Svetlana V. Belitser, et al.. (2009). Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 15(2). 231–241. 95 indexed citations
11.
12.
13.
Cate, R. ten, D. M. C. Brinkman, Arjan C. Lankester, et al.. (2002). Macrophage activation syndrome after autologous stem cell transplantation for systemic juvenile idiopathic arthritis. European Journal of Pediatrics. 161(12). 685–686. 15 indexed citations
14.
Duggan, Peter, Karen Booth, A Chaudhry, et al.. (2002). Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplantation. 30(10). 681–686. 55 indexed citations
15.
McClain, Kenneth L., et al.. (2002). Need for a cooperative study: Pulmonary langerhans cell histiocytosis and its management in adults. Medical and Pediatric Oncology. 39(1). 35–39. 14 indexed citations
16.
Sluis, Peter van, Jan de Kraker, J.P.M. Bökkerink, et al.. (1997). A constitutional balanced 1;17 neuroblastoma translocation. European Journal of Cancer. 33(12). 2136–2136. 1 indexed citations
17.
Bhatia, Ravi, Mark E. Nesbit, Maarten Egeler, et al.. (1997). Epidemiologic study of Langerhans cell histiocytosis in children. The Journal of Pediatrics. 130(5). 774–784. 89 indexed citations
18.
Caron, Huib N., Peter van Sluis, Jan de Kraker, et al.. (1996). Allelic Loss of Chromosome 1p as a Predictor of Unfavorable Outcome in Patients with Neuroblastoma. New England Journal of Medicine. 334(4). 225–230. 326 indexed citations
19.
Nézelof, C, Maarten Egeler, Peter Bucsky, & Jean Gogusev. (1995). Malignant histiocytosis in childhood: A disease in quest of new nosological criteria. Medical and Pediatric Oncology. 25(2). 67–69. 4 indexed citations
20.
Loechelt, Brett, Maarten Egeler, Alexandra H. Filipovich, Harumi Jyonouchi, & Ralph Shapiro. (1994). Immunosuppression: Preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL). Medical and Pediatric Oncology. 22(5). 325–328. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maurizio Miano Breakdown of academic impact, for papers by Dragana Janić Breakdown of academic impact, for papers by Der-Cherng Liang Breakdown of academic impact, for papers by Susan R. Wiersma Breakdown of academic impact, for papers by Kate Wheeler Breakdown of academic impact, for papers by Teena Bhatla Breakdown of academic impact, for papers by J Akatsuka Breakdown of academic impact, for papers by Mary Taj Breakdown of academic impact, for papers by Ronald L. Chard Breakdown of academic impact, for papers by Meerim Park
Rankless by CCL
2026